VBI Vaccines (VBIV) – Analyst Comments
-
"Remain Encouraged by VBI-1901's Performance" - Oppenheimer Reiterates VBI Vaccines (VBIV) at Outperform with $8 Price Target
-
Oppenheimer Reiterates VBI Vaccines (VBIV) at Outperform, ACIP Recommendation Sets Stage for PreHevbrio Coverage
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to VBIV Stock Lookup